PressOctober 16, 2022 Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
PressOctober 14, 2022 Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference
PressOctober 14, 2022 Clearmind Medicine Announces Share-Based Payment for one of the Company’s Consultants
PressOctober 14, 2022 Wellbeing Digital and Subsidiary KGK Science Applauds the Government of Alberta’s Move to Regulate the Use of Psychedelics
PressOctober 13, 2022 Love Pharma – Johns Hopkins University Psilocybin Trial Advances Toward Launch in 2022
PressOctober 13, 2022 PSYC’s Spotlight Media Highlights Revenue Growth and Other Operational Achievements Met in Q3
PressOctober 13, 2022 IntelGenx Says Atai Life Sciences Collaboration Leads to Start of First-in-Human Clinical Study of Oral Thin Film Psychedelic Drug Candidate
PressOctober 13, 2022 Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
PressOctober 13, 2022 Clairvoyant’s Phase 2 Psilocybin Therapy Trial for Alcohol Use Disorder Obtains Regulatory Approval and Initiates 1st Clinical Site in Finland
PressOctober 12, 2022 COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
PressOctober 12, 2022 atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
PressOctober 12, 2022 Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference
PressOctober 12, 2022 Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference
PressOctober 11, 2022 PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial
PressOctober 10, 2022 Silo Pharma’s Mission To Merge Traditional Pharmaceuticals With Psychedelic Compounds Can Be A Treatment Game-Changer For Neurological Disorders
PressOctober 10, 2022 Core One Labs Nearing GMP Production as Canada’s Province of Alberta Announces Game Changing Legislation
PressOctober 10, 2022 ALTRD.TV’s Open Minds Documentary Explores the Promising Future of Psychedelic Medicine
PressOctober 10, 2022 Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia
